BAJAJ BROKING

Notification
No new Notification messages
Ather Energy IPO is Open!
Apply for the Ather Energy IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

Zydus Lifesciences Q3 Results FY24-25: Revenue grows 17% to ₹5,269.1 Crore, Net Profit climbs 30% to ₹1,023.5 Crore

Zydus Lifesciences Q3 Results FY24-25: Revenue grows 17% to ₹5,269.1 Crore, Net Profit climbs 30% to ₹1,023.5 Crore

Zydus Lifesciences has announced its consolidated financial results for the third quarter of FY24-25, reporting total revenue from operations of ₹5,269.1 million and a net profit of ₹1,023.5 crore. The company recorded a profit before tax (PBT) of ₹1,184.1 crore, with total expenses amounting to ₹4,142.5 crore. Key financial components include finance costs of ₹32 crore and other expenses of ₹1,534.2 crore. The pharmaceuticals segment contributed ₹4,809.9 crore in revenue, while the consumer products segment added ₹459.2 crore. These results underscore the company's strong financial performance and operational efficiency for the quarter.

ZYDUS LIFESCIENCES LTD

Trade

888.250.20 (0.02 %)

Updated - 30 April 2025
901.85day high
DAY HIGH
883.00day low
DAY LOW
907542
VOLUME (BSE)

Key Highlights/Quick Insights

  • Total Revenue from Operations: ₹5,269.1 crore, up 17% from last year.

  • Net Profit: ₹1,023.5 crore, up 30% over last year.

  • Profit Before Tax (PBT): ₹1,184.1 crore

  • Finance Costs: ₹32 crore

  • Other Expenses: ₹1,534.2 crore

  • Total Expenses: ₹4,142.5 crore

  • Segment Contribution:

    • Pharmaceuticals Revenue: ₹4,809.9 crore

    • Consumer Products Revenue: ₹459.2 crore

Quarterly - Zydus Life Q3 Results FY24-25

Zydus Lifesciences posted strong revenue growth in Q3 FY24-25, showcasing its resilience and strategic execution. The company’s total revenue stood at ₹5,269.1 crore, marking a notable increase compared to the previous year’s ₹4,505.2 crore.

The net profit for the quarter came in at ₹1,023.5 crore, reflecting solid bottom-line growth. The company’s cost management and operational efficiencies contributed to the overall profitability.

Segment Highlights

  • Pharmaceuticals Segment

    • Revenue: ₹4,809.9 crore

    • Profit Before Tax: ₹1,175.3 crore

    • Steady growth across key product categories

  • Consumer Products Segment

    • Revenue: ₹459.2 crore

    • Profit Before Tax: ₹8.8 crore

    • Continued expansion in consumer health business

Sector Expectations for Zydus Lifesciences 3Q Results FY24-25

The pharmaceutical sector recorded total revenue from operations of ₹5,269.1 crore in Q3 FY24-25. Zydus Lifesciences reported a profit before tax (PBT) of ₹1,184.1 crore, with a net profit of ₹1,023.5 crore. The pharmaceuticals segment contributed ₹4,809.9 crore, while the consumer products segment accounted for ₹459.2 crore. The company's operational efficiencies and global sales have bolstered its financial performance this quarter.

Management Commentary

Zydus Lifesciences, a global life sciences company engaged in the discovery, development, manufacturing, and marketing of a range of healthcare therapies, reported its financial results for the third quarter, outlining performance across its business segments. The company recorded contributions from both the pharmaceuticals and consumer products segments, with key financial metrics remaining in line with the previous quarter. As part of the Zydus Group, which employs over 27,000 people worldwide, the company continues its operations in healthcare solutions and maintains a presence in global markets.

Financial Table (Consolidated)

Particulars

Q3 FY24-25 (₹ Crore)

Q2 FY24-25 (₹ Crore)

Q3 FY23-24 (₹ Crore)

Revenue from Operations

5,269.1

5,237

4,505.2

Profit Before Tax (PBT)

1,184.1

1,270.9

925.5

Net Profit

1,023.5

911.2

789.6

Total Expenses

4,142.5

4,034.3

3,617.4

Depreciation and Amortisation

229

233.6

194.8

Finance Costs

32

25.1

19.8

Other Expenses

1,534.2

1,470.4

1,137.6

Pharmaceuticals Revenue

4,809.9

4,747.5

4,105.3

Consumer Products Revenue

459.2

489.5

399.9

Source: Zydus Lifesciences' Financial Data submitted to BSE.

Do you have a trading account app or demat account app?

You can open an account with Bajaj Broking in minutes.

Download the Bajaj Broking app now from Play Store or App Store.

Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.

This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.

For All Disclaimers Click Here: https://www.bajajbroking.in/disclaimer

Share this article: 

Read More Blogs

Disclaimer :

The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.

The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.

Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.

BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.

Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.

[ Read More ]

For more disclaimer, check here : https://www.bajajbroking.in/disclaimer

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

9.5 lakh+ Users

icon-with-text

4+ App Rating

icon-with-text

4 Languages

icon-with-text

₹4400+ Cr MTF Book

icon-with-text